SCHEDULE: Perceptive Advisors Amends Beta Bionics Stake
Beneficial Ownership Report Amendment
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed an amendment to their Schedule 13G, restating their beneficial ownership in Beta Bionics, Inc. at 3.68%.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Beta Bionics, Inc.
- The filing restates their beneficial ownership of 1,593,608 shares of Beta Bionics, Inc. Common Stock.
- This represents 3.68% of the company's outstanding Common Stock.
- The ownership percentage is calculated based on 43,348,840 shares outstanding as of March 1, 2025, as reported in Beta Bionics' Form 10-K/A filed on March 28, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the shares, with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as the managing member of Perceptive Advisors LLC.
- All three reporting persons share voting and dispositive power over the 1,593,608 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is an amendment to a Schedule 13G, restating the beneficial ownership percentage of Perceptive Advisors and related entities in Beta Bionics, Inc. at 3.68%. It does not indicate a new acquisition or disposition that would significantly alter the market's perception of the company or the investor's stance, thus maintaining a neutral sentiment.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of institutional ownership, common in the financial industry. Perceptive Advisors is an investment firm specializing in the life sciences sector, indicating their continued interest in Beta Bionics, Inc., a company likely operating in that space.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, confirming Perceptive Advisors' continued stake.
- Investment Professionals: Offers insight into the holdings of a notable life sciences investor in Beta Bionics.
Key Dates
| Date | Description |
|---|---|
| 2025-03-01 | Date as of which Beta Bionics, Inc. reported 43,348,840 shares of Common Stock outstanding in its Annual Report on Form 10-K/A. |
| 2025-03-28 | Date Beta Bionics, Inc. filed its Annual Report on Form 10-K/A with the SEC. |
| 2025-03-31 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-08-07 | Date the Amendment No. 1 to Schedule 13G was signed and filed. |
Keywords
Beta Bionics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.